Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma
暂无分享,去创建一个
H. Zeng | Junru Chen | Jinge Zhao | Xingming Zhang | P. Shen | Jia Wang | G. Sun | Jiandong Liu | Yaojing Yang | P. Zhao | Q. Tang | K. Shu